S.A. Mason’s GSK GSK Stock Holding History

S.A. Mason’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-640	Closed	-$24.6K	–	295
2025 Q2	$24.6K	Hold	640	–	–	0.01%	328
2025 Q1	$24.8K	Hold	640	–	–	0.01%	313
2024 Q4	$21.6K	Hold	640	–	–	0.01%	312
2024 Q3	$26.2K	Hold	640	–	–	0.01%	293
2024 Q2	$24.6K	Hold	640	–	–	0.01%	287
2024 Q1	$27.4K	Hold	640	–	–	0.02%	276
2023 Q4	$23.7K	Hold	640	–	–	0.02%	275
2023 Q3	$23.2K	Hold	640	–	–	0.02%	279
2023 Q2	$22.8K	Hold	640	–	–	0.02%	282
2023 Q1	$22.8K	Hold	640	–	–	0.02%	282
2022 Q4	$22.5K	Hold	640	–	–	0.02%	284
2022 Q3	$19K	Hold	640	–	–	0.02%	291
2022 Q2	$35K	Hold	640	–	–	0.03%	275
2022 Q1	$35K	Hold	640	–	–	0.02%	281
2021 Q4	$35K	Hold	640	–	–	0.02%	279
2021 Q3	$31K	Hold	640	–	–	0.02%	276
2021 Q2	$32K	Hold	640	–	–	0.02%	269
2021 Q1	$29K	Hold	640	–	–	0.02%	265
2020 Q4	$29K	Hold	640	–	–	0.02%	255
2020 Q3	$30K	Sell	640 -8	-1%	-$401	0.03%	235
2020 Q2	$33K	Hold	648	–	–	0.03%	233
2020 Q1	$31K	Buy	648 +8	+1%	+$427	0.04%	235
2019 Q4	$38K	Buy	+640	New	+$35.6K	0.04%	246

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

S.A. Mason's GSK Position: Q3 2025 in Review

S.A. Mason sold out of GSK (GSK) in Q3 2025, closing a stake of 640 shares — an estimated $24.6K sold.

S.A. Mason first reported a position in GSK in Q4 2019 and held it in 23 quarters. The position peaked at $38K in Q4 2019. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

S.A. Mason reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
S.A. Mason sold 640 GSK shares in Q3 2025, an estimated $24.6K.
S.A. Mason first reported a position in GSK in Q4 2019 and held it in 23 quarters.
S.A. Mason's GSK position peaked at $38K in Q4 2019.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on S.A. Mason's 13F filing for Q3 2025, filed 14 Oct 2025.